• A unique finding in this study is

  2025-01-15

  

  A unique finding in this study is that 12/15-LO influences CREB phosphorylation in the murine brain. While previous reports have found that knockout of 5-lipoxygenase, a related enzyme that also uses arachidonic 89 6 for substrate, can regulate CREB phosphoryation in the context of Alzheimer's dise

• Introduction The corpus luteum CL is a transient

  2025-01-15

  

  Introduction The corpus luteum (CL) is a transient endocrine gland that differentiates from the thecal and granulosal cells of the ovarian follicle after ovulation. Its formation and limited lifespan in the mammalian ovary is important for fertility, as the CL produces progesterone (P4), the essent

• br Concluding remarks br Definition Prion

  2025-01-15

  

  Concluding remarks Definition Prion diseases are fatal neurodegenerative disorders that are caused by an unconventional agent that is neither bacterial nor viral, but is in essence an infectious misfolded amyloidogenic protein, termed a prion (Prusiner, 1982). Once considered highly controvers

• br Conclusions and perspectives In view of

  2025-01-15

  

  Conclusions and perspectives In view of the evidences supporting that Isochlorogenic acid B MAS receptors mediate the effects of AT1 antagonists (Iwai et al., 2012, Ohshima et al., 2014, Pernomian et al., 2015, Schuchard et al., 2015), the prime targets from the perspectives on future directions

• A candidate protein for the regulation of AMPAR transport

  2025-01-15

  

  A candidate protein for the regulation of AMPAR transport is CaMKII, a Ca2+-dependent kinase with diverse cellular functions. With respect to synaptic transmission, CaMKII is recognized as a key synaptic protein that is required to modify the number of synaptic AMPARs in response to LTP and LTD stim

• In the present study AP

  2025-01-15

  

  In the present study, AP31-B preferentially released hydrophobic Angiogenesis inhibitor such as leucine and alanine from N-terminal of peptide (Fig. 4). The debittering ability of AP31-B seemed to depend on such substrate specificity, but additional tests against other hydrophobic amino acids are n

• The clinical impact of our findings is also supported by

  2025-01-15

  

  The clinical impact of our findings is also supported by our earlier report that the level of 12-LOX expression was correlated with the tumor stage and grade [17], [52] and that overall, 38% of patients demonstrated elevated levels of 12-LOX in prostate cancer tissue compared with their matching nor

• It thus appeared reasonable that AR needed to

  2025-01-15

  

  It thus appeared reasonable that AR needed to be inhibited and great experimental efforts began which are still on-going [6]. Indeed, hundreds of ARIs have been characterized but no significant drug development has followed. The case of Sorbinil, which did not pass clinical trials is emblematic [7]

• NMDA receptor compound Our initial approach to identify hits

  2025-01-14

  

  Our initial approach to identify hits was two-pronged and included a high-throughput screening (HTS) campaign of the OSI NMDA receptor compound library as well as a virtual screening (VS) campaign, utilizing a publically available crystal structure of ACK1 (PDB code: ). A tolerance for protein flex

• The results show that a tonic action of ACh on

  2025-01-14

  

  The results show that a tonic action of ACh on respiration is lacking. However, it is clear that muscarinic cholinergic mechanisms can modulate both eupneic breathing and the cough reflex. When these mechanisms are brought into action is obscure and only tentative proposals can be advanced. ACh in t

• In the U S surveillance of ACEs has

  2025-01-14

  

  In the U.S., surveillance of ACEs has garnered traction at the state level through administration of the ACE Optional Module in CDC’s Behavioral Risk Factor Surveillance System (BRFSS) (Centers for Disease Control & Prevention, 2003). Since 2009, select states have implemented the ACEs optional modu

• There are profound differences between acute and chronic

  2025-01-14

  

  There are profound differences between acute and chronic pain when dramatic changes occur in peripheral nociceptors and central nociceptive pathways and the pain system is sensitised thereby leading to exaggerated responses to noxious stimuli (hyperalgesia) and responses to non-noxious stimuli (allo

• Several structural classes of ASK

  2025-01-14

  

  Several structural Genipin of ASK1 inhibitors, mostly from industry but also from academia, have been identified over the last decade. In 2012, Terao et al. (Takeda) reported imidazo[1,2-α]pyridine () as a potent ASK1 inhibitor derived from structure-based drug design. GSK, Merck and Gilead revealed

• br Angiotensin receptor neprilysin inhibitors Sacubitril

  2025-01-13

  

  Angiotensin receptor-neprilysin inhibitors Sacubitril/valsartan is the first-in-class ARNI, comprising of molecular moieties of valsartan (ARB) and a neprilysin inhibitor prodrug, sacubitril (AHU377) [51]. Upon ingestion, sacubitril is rapidly metabolised into an active neprilysin inhibitor, sacu

• Pathogen infected macrophages release exosomes associating w

  2025-01-13

  

  Pathogen-infected MHY1485 release exosomes associating with pathogen-associated molecular patterns (PAMPs) such as LPS and lipoprotein derived from microorganisms [29,30]. Exosomes released by bacterially infected, but not uninfected, macrophages stimulate macrophages to release inflammatory mediat

15586 records 1/1040 page Next 12345 下5页 Last page